Communication Tools

Access templates to inform healthcare teams and patients of important policy changes, vaccine recommendations, and standards of care.

Resources For Health Systems

Newsletter to share the CDC adult hepatitis B vaccination recommendations with your team.
Download this newsletter to share the CDC adult hepatitis B vaccination recommendations with your team.
Email template to inform your healthcare team about the CDC adult hepatitis B vaccination recommendations.
Copy and fill out this template to inform your team about the CDC adult hepatitis B vaccination recommendations via email.
Click to copy template
to your clipboard
Templated Email to Healthcare Team #1
Email template to inform your healthcare team about EHR system updates.
Copy and fill out this template to inform your team about important updates to your EHR system via email.
Click to copy template
to your clipboard
Templated Email to Healthcare Team #2

Resources For Patient Communication

Email template to inform your patients about the CDC adult hepatitis B vaccination recommendations.
Copy and fill out this template to inform your patients about the CDC adult hepatitis B vaccination recommendations via email.
Click to copy template
to your clipboard
Templated Email to Patient #1
Email template to remind your patient to schedule a hepatitis B vaccination appointment.
Copy and fill out this template to remind your patients to schedule a hepatitis B vaccination appointment.
Click to copy template
to your clipboard
Templated Email to Patient #2
EHR chart message template to inform your patients about the CDC adult hepatitis B vaccination recommendations.
Copy and fill out this template to inform your patients about the CDC adult hepatitis B vaccination recommendations via EHR chart messages.
Click to copy template
to your clipboard
Patient Chart Message Template

CDC, Centers for Disease Control and Prevention; EHR, electronic health record. 

Important Safety Information

INDICATION

HEPLISAV-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. 

IMPORTANT SAFETY INFORMATION

Do not administer HEPLISAV-B to individuals with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of HEPLISAV-B, including yeast. 

Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of HEPLISAV-B. 

Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to HEPLISAV-B. 

Hepatitis B has a long incubation period. HEPLISAV-B may not prevent hepatitis B infection in individuals who have an unrecognized hepatitis B infection at the time of vaccine administration. 

The most common patient-reported adverse reactions reported within 7 days of vaccination were injection site pain (23%-39%), fatigue (11%-17%), and headache (8%-17%). 

Please see full Prescribing Information.